Platforms
Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-05Jul 15, 2025
CLD
Advancing Biologics Development With Next-Generation Cell Line Development
Woo Chi, Ph.D.; Yingji Jin, Ph.D.; Jaeeun Kim
Samsung Biologics
PAO-06-25-CL-06Jun 16, 2025
Drug Development
Podcast: Insights from CDO Experts from Samsung Biologics
Jiyeon Lee; Hyelyoung Jang
Samsung Biologics
POD-01-24-CL-01Jan 16, 2024
CMC
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.
Wheeler Bio
PAO-07-23-CL-05Jul 26, 2023
Cell Line Development Technology
Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering
Wheeler Bio
PR-M11-22-09Nov 30, 2022
Cell Line Development
Integrating Cell Line and CMC Development
Stephen Hamilton, Ph.D.; Mike Brem
Wheeler Bio
PAO-06-022-CL-12Sep 02, 2022
Cell Line Development
Wheeler Bio Integrates the Solentim® Ecosystem by Advanced Instruments to Deliver the Highest Level of Consistency Across Their Cell Line Development Workflow
Advanced Instruments
PR-M06-22-04Jun 14, 2022
Capacity Expansion
German CDMO Richter-Helm Triples cGMP Production Capacity to Accommodate Global Market Demand
Richter BioLogics
PR-M05-21-008May 12, 2021
Cell Line Development
Rising Demand for Novel Cancer Treatment Approaches to Propel Cell Line Development Market through 2024
Global Market Insights
PAO-M11-19-NI-007Nov 20, 2019
Strategic Collaboration
Berkeley Lights and TPG Biologics Enter into a Strategic Collaboration for Cell Line Development
Berkeley Lights
PR-M05-18-NI-099May 25, 2018